Print

DCVax-001

A Randomized, Placebo-controlled, Dose-escalating, Double-blinded Phase I Study to Evaluate the Safety and Immunogenicity of Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) With Poly ICLC (Hiltonol) as Adjuvant in HIV-uninfected Healthy Volunteers

Trial Details:

I Completed
Rockefeller, Collaboration for AIDS Vaccine Discovery (CAVD) May 01, 2010
DEC-205-p24gag Gag a single-chain Fv antibody specific for the DC-restricted antigen-uptake receptor DEC205.
DCVax-001 Protein
USA 45
NCT01127464
http://clinicaltrials.gov/ct2/show/NCT01127464?term=DEC+205+AND+NY&rank=1